TrialNature communications2025

Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial.

Peng-Fei Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.